iCAD Announces Increased Adoption of iReveal® Automated Breast Density Solution in U.S.
Momentum reflects response to state mandated breast density notifications and healthcare provider confidence in iCAD's radiology workflow solution platform
NASHUA, N.H., -- iCAD (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced positive momentum in U.S. sales of its iReveal® automated breast density system, as adoption expands into several new markets.
The Company launched iReveal in July 2015 as the latest addition to the iCAD PowerLook® Advanced Mammography Platform. The iReveal software is designed to deliver automated, rapid and reproducible breast density assessments to help identify patients who may experience reduced sensitivity to digital mammography due to dense breast tissue. The PowerLook platform is the hub that supports the breast density module, 2D computer-aided detection (CAD) and future 3D solutions, such as density and concurrent read tomosynthesis software.Â
"Now that 27 U.S. states have enacted laws requiring hospitals to inform patients about their breast density, we are especially pleased that this leading solution is being recognized by more healthcare facilities nationwide for the benefits it delivers to clinicians and patients," said Ken Ferry, CEO of iCAD. "Our iReveal technology rapidly produces consistent breast density results while reducing the risk of reader variability. As a result, radiologists may be better able to identify women who can benefit from additional screening."
An estimated 40% of women in the U.S. have dense breast tissue, which can mask potential cancers in mammography screening.(i) For women with dense breasts, mammography sensitivity is reduced to approximately 48% from an average of 98%.(ii)Â
The iReveal automated workflow tool efficiently and accurately assesses breast density, then assigns the patient to a specific category established by the American College of Radiology's (ACR) Breast Imaging Reporting and Data System (BI-RADS®). Patients with dense breast tissue may be recommended for additional screening exams, including use of breast tomosynthesis.
"iReveal takes the guess work out of breast density assessments," according to Jason Stiver, radiology department manager at Punxsutawney Area Hospital (PAH), where iReveal was recently adopted. "Before iReveal, our prior breast density reporting solution was relatively subjective, and results could vary greatly from one radiologist to another. However, iReveal is automated and was seamlessly incorporated into our practice with virtually no learning curve required."
In addition to PAH, other medical facilities that have recently adopted iReveal technology include: Phelps County Regional Medical Center in Rolla, MO; Catholic Medical Center in Manchester, NH; Karmanos Cancer Institute in Detroit, MI; Maine Coast Memorial Hospital in Ellsworth, ME; and Olmsted Medical Center in Rochester, MN.
"I am extremely pleased with iReveal, as the solution's clinical support decision scorecard is extremely accurate and helps me make more informed decisions," noted Mohammed Omar Khalaf Al-Tawil, MD, diagnostic radiology specialist at PAH.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit www.icadmed.com or www.xoftinc.com.
(i) Sprague LB, et al. Prevalence of Mammographically Dense Breasts in the United States. JNCI J Natl Cancer Inst. 2014;106(10): dju255 doi:10.1093/jnci/dju255.
(ii) Kolb TM, Lichy J, Newhouse JH. "Comparison of the Performance of Screening Mammography, Physical Examination, and Breast US and Evaluation of Factors that Influence Them: An Analysis of 27,825 Patient Evaluations. Radiology 2002;225(1):165-75.
Web Site: http://www.icadmed.com
